EX-99.1 2 aimd_ex991.htm PRESS RELEASE EXHIBIT 99.1 Ainos Reports Full Year 2023 Financial Results Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024 Advancing VELDONA drug candidates to Phase III clinical studies Expanding market of AI Nose-powered VOC-sensing technology with strategic partners NISD and Inabata SAN DIEGO, March 8, 2024 /Accesswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the developm ...

Ainos (NASDAQ:AIMD) stock is on the move Monday as the healthcare company’s shares experienced heavy trading this morning.Ainos stock is experiencing strong pre-market trading on Monday as more than 7 million shares of the stock have changed hands. That’s a massive surge compared to its daily average trading volume of about 637,000 shares.Investors will note that there is no clear news from the company that explains today’s rally. That includes a lack of press releases or filings with the Securities and Exc ...

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that Jack Lu, the Company's Director of Corporate Development, will present live at the Small-Cap Growth Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on February 7, 2024. DATE: February 7 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 10-Q _____________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 0-20791 _________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____to____ Commission File No. 0-20791 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 75-1974352 (State or other jurisdiction (IRS Emp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____to____ Commission File No. 0-20791 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 75-1974352 (State or other jurisdiction of (IRS ...

U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 [Fee Required] For the Fiscal Year Ended December 31, 2022 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 [No Fee Required] Commission File Number 0-20791 AINOS, INC. (Exact name of registrant as specified in its charter) Texas 75-1974352 (State or other jurisdiction of incorporation or organization) ( ...